

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use INTRALIPID® safely and effectively. See full prescribing information for INTRALIPID.

INTRALIPID 20% (lipid injectable emulsion), for intravenous use
Initial U.S. Approval: 1975

RECENT MAJOR CHANGES

Boxed Warning (Removed)	5/2023
Dosage and Administration (2.3)	5/2023
Contraindications (4)	5/2023
Warnings and Precautions (5.1)	5/2023

INDICATIONS AND USAGE

Intralipid is indicated as a source of calories and essential fatty acids for adult and pediatric patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).

DOSAGE AND ADMINISTRATION

- For intravenous infusion into a peripheral or central vein. (2.1)
- Intralipid Pharmacy Bulk Package is only indicated for use in pharmacy admixture program for the preparation of three-in-one or total nutrition admixtures (TNAs). (2.2)
- Protect the admixed PN solution from light. (2.2, 16)
- Recommended dosage depends on age, energy expenditure, clinical status, body weight, tolerance, ability to metabolize and eliminate lipids, and consideration of additional energy given to the patient. (2.3)

Age	Nutritional Requirements	
	Initial Recommended Dosage	Maximum Dosage
Birth to 2 years of age (including preterm and term neonates)	0.5 g/kg/day	3 g/kg/day
Pediatric patients 2 to <12 years of age	1 to 2 g/kg/day	2.5 g/kg/day
Pediatric patients 12 to 17 years of age	1 g/kg/day	2 g/kg/day
Adults	1 g/kg/day (stable) ≤1 g/kg/day (critically ill)	2.5 g/kg/day

DOSAGE FORMS AND STRENGTHS

20% Injectable emulsion:

- 20 g/100 mL (0.2 g/mL) of lipid in 100 mL single-dose flexible container (3)
- 50 g/250 mL (0.2 g/mL) of lipid in 250 mL single-dose flexible container (3)
- 100 g/500 mL (0.2 g/mL) of lipid in 500 mL single-dose flexible container (3)
- 200 g/1,000 mL (0.2 g/mL) of lipid in 1,000 mL Pharmacy Bulk Package (3)

CONTRAINDICATIONS

- Known hypersensitivity to egg, soybean, or peanut, or any of the active ingredients or excipients. (4, 5.3)
- Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride > 1,000 mg/dL). (4, 5.7)

WARNINGS AND PRECAUTIONS

- Risk of Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsion in Neonates and Infants:** Acute respiratory distress, metabolic acidosis, and death after rapid infusion of intravenous lipid emulsions have been reported. (5.1, 8.4)
- Risk of Parenteral Nutrition-Associated Liver Disease (PNALD):** Increased risk in patients who receive PN for extended periods of time, especially preterm neonates. Monitor liver function tests; if abnormalities occur consider discontinuation or dosage reduction. (5.2, 6.1, 8.4)
- Hypersensitivity Reactions:** Monitor for signs or symptoms. Discontinue infusion if reactions occur. (5.3)
- Risk of Infections, Fat Overload Syndrome, Refeeding Syndrome, and Hypertriglyceridemia:** Monitor for signs and symptoms; monitor laboratory parameters. (5.4, 5.5, 5.6, 5.7)
- Aluminum Toxicity:** Increased risk in patients with renal impairment, including preterm neonates. (5.8, 8.4)

ADVERSE REACTIONS

Most common adverse drug reactions (≥5%) from clinical trials in adults were nausea, vomiting, and pyrexia. Most common adverse drug reactions (≥5%) from clinical trials in pediatric patients were anemia, vomiting, increased gamma-glutamyltransferase, and cholestasis. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Vitamin K Antagonists (e.g., warfarin): Anticoagulant activity may be counteracted; increase monitoring of coagulation parameters. (7)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 5/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

- INDICATIONS AND USAGE
- DOSAGE AND ADMINISTRATION
 - Important Administration Instructions
 - Preparation Instructions
 - Recommended Dosage and Administration
- DOSAGE FORMS AND STRENGTHS
- CONTRAINDICATIONS
- WARNINGS AND PRECAUTIONS
 - Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsion in Neonates and Infants
 - Parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders
 - Hypersensitivity Reactions
 - Infections
 - Fat Overload Syndrome
 - Refeeding Syndrome
 - Hypertriglyceridemia
 - Aluminum Toxicity
 - Monitoring/Laboratory Tests
- ADVERSE REACTIONS
 - Clinical Trials Experience
 - Postmarketing Experience
- DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- Pregnancy
- Lactation
- Pediatric Use
- Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- Mechanism of Action
- Pharmacodynamics
- Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- Adult Clinical Studies
- Pediatric Clinical Studies

16 HOW SUPPLIED/ STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

- * Sections or subsections omitted from the full prescribing information are not listed.

1 **FULL PRESCRIBING INFORMATION**

2 **1 INDICATIONS AND USAGE**

3 Intralipid[®] is indicated as a source of calories and essential fatty acids for adult and pediatric
4 patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention
5 of essential fatty acid deficiency (EFAD).


6 **2 DOSAGE AND ADMINISTRATION**

7 **2.1 Important Administration Instructions**

- 8 • Intralipid is prepared and administered by a healthcare provider in the inpatient setting.
9 Patients and caregivers may prepare and administer Intralipid for home use after appropriate
10 training by a trained healthcare provider.
- 11 • Intralipid is for intravenous infusion into a central or peripheral vein.
- 12 • Do not exceed the recommended maximum infusion rate in Table 1 [*see Dosage and*
13 *Administration (2.3) and Warnings and Precautions (5.1)*].
- 14 • Intralipid admixtures with osmolarity
15 o Greater than or equal to 900 mOsm/L must be infused through a central vein.
16 o Less than 900 mOsm/L may be administered either through a central or peripheral vein.
- 17 • Use a 1.2 micron in-line filter during administration.
- 18 • Use a dedicated infusion line without any connections. Do not connect multiple medications
19 in series.
- 20 • To prevent air embolism, use a non-vented infusion set or close the vent on a vented set and
21 fully evacuate residual gas in the bag prior to administration.
- 22 • Do not pressurize the flexible bag to increase flow rates, and if administration is controlled
23 by a pumping device, turn off the pump before the bag runs dry.
- 24 • Do not use infusion sets and lines that contain di-2-ethylhexyl phthalate (DEHP), including
25 infusion sets that contain polyvinyl chloride (PVC) components, because they contain DEHP
26 as a plasticizer.
- 27 • Intralipid can be infused concurrently into the same vein as dextrose-amino acid solutions (as
28 part of PN) by a Y-connector located near the infusion site; flow rates of each solution
29 should be controlled separately by infusion pumps.
- 30 • After connecting the infusion set, start infusion of Intralipid immediately. Complete the
31 infusion within 12 hours when using a Y-connector and within 24 hours when used as part
32 of an admixture.

33 **2.2 Preparation Instructions**

34 Use the following instructions to prepare single-dose 100 mL, 250 mL, and 500 mL Flexible
35 containers for administration:




1. Inspect Bag

- Inspect the integrity indicator (Oxalert[®]) (A) before removing the overpouch.
- Discard the product if the indicator is black,


40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72

overpouch is opened or damaged, emulsion color is not white, or seals of bag are broken.




2. Remove Overpouch

- Place the bag on a clean, flat surface.
- Tear the overpouch at notch and pull down.
- Discard the Oxalert sachet (A) and the oxygen absorber (B).
- Visually inspect the bag and contents for particulate matter and discoloration prior to administration. The lipid emulsion should be a homogenous liquid with a milky white appearance. If the mixture is not white or the emulsion has separated (noted by discoloration, phase separation, or oily droplets), or if particulates and/or leakage are observed, discard the bag.




3. Spike Bag

- Identify the infusion port (**blue** cap with the arrow pointing away from the bag).
- Immediately before inserting the infusion set, break off the **blue** infusion port cap.
- Use infusion sets according to ISO Number 8536-4 with an external spike diameter of 5.5 to 5.7 mm and use a non-vented infusion set or close the air-inlet on a vented set.
- Use a 1.2 micron in-line filter for administration.
- Hold the base of the infusion port.
- Insert the spike through the infusion port by rotating your wrist slightly until the spike is inserted.
- Do not pierce the infusion port more than once.



4. Hang the bag

- On the hanger cut and start infusion.
- Discard unused portion.



73 Intralipid 100 mL, 250 mL, and 500 mL single-dose Flexible Containers

- After removing the overpouch, infuse immediately. If not used immediately, the product should be stored at 2°C to 8°C (36°F to 46°F) for no longer than 24 hours. After removal from storage, infuse within 12 hours when using a Y-connector and within 24 hours when used as part of an admixture.

78 Intralipid 1,000 mL Pharmacy Bulk Package

- 79 • *For admixing use only and not for direct intravenous infusion.* Prior to administration,
80 transfer to a separate PN container for individual patient use.
- 81 • Transfer the contents through the blue infusion port using a suitable sterile transfer device or
82 dispensing set. Discard any unused contents.
- 83 • Use the Pharmacy Bulk Package immediately for admixing after removal from the overpouch.
84 If not used immediately, the product can be stored for no longer than 24 hours at 2°C to 8°C
85 (36°F to 46°F). After removal from storage, and once the closure is penetrated, use
86 Pharmacy Bulk Package contents within 4 hours.

87 Admixing Instructions

- 88 • Prepare the admixture in PN containers using strict aseptic techniques to avoid microbial
89 contamination.
- 90 • Do not add Intralipid to the PN container first; destabilization of the lipid may occur. The
91 prime destabilizers of emulsions are excessive acidity (such as a pH <5) and inappropriate
92 electrolyte content. Amino acid solutions exert buffering effects that protect the emulsion
93 from destabilization. Give careful consideration to the addition of divalent cations (Ca⁺⁺ and
94 Mg⁺⁺), which have been shown to cause emulsion instability.
- 95 • Do not inject additives directly into Intralipid.
- 96 • Intralipid may be mixed with amino acid and dextrose injections to produce “all-in-one” PN
97 admixtures. The mixing sequence below must be followed for manual compounding to
98 minimize pH-related problems by ensuring that typically acidic dextrose injections are not
99 mixed with lipid emulsions alone; shake bags gently after each addition.
 - 100 ○ Transfer dextrose injection to the PN container.
 - 101 ○ Transfer amino acid injection.
 - 102 ○ Transfer Intralipid.
- 103 • Simultaneous transfer of amino acid injection, dextrose injection, and Intralipid to the PN
104 container is also permitted; follow automated compounding device instructions as indicated.
105 Use gentle agitation during admixing to minimize localized concentration effects.
- 106 • Additions to the PN admixtures should be evaluated by a pharmacist for compatibility.
107 Questions about compatibility may be directed to Baxter Healthcare.
- 108 • Inspect the admixture to ensure that precipitates have not formed during preparation of the
109 admixture and the emulsion has not separated. Discard the admixture if any of the above are
110 observed.
- 111 • Infuse admixtures containing Intralipid immediately. If not used immediately, store
112 admixtures under refrigeration at 2°C to 8°C (36°F to 46°F) for no longer than 24 hours.
113 Infusion must be complete within 24 hours after removal from refrigeration. Discard any
114 remaining admixture.
- 115 • Protect the admixed PN solution from light.

116 **2.3 Recommended Dosage and Administration**

- 117 • The recommended nutritional requirements of lipid and recommended dosages of Intralipid
118 to be administered to meet those requirements for adults and pediatric patients are provided in

- 119 Table 1, along with recommendations for the initial and maximum infusion rates.
- 120 • The dosing of Intralipid depends on the patient’s individual energy requirements influenced
- 121 by age, body weight, tolerance, clinical status, and the ability to metabolize and eliminate
- 122 lipids.
- 123 • When determining dose, energy supplied by dextrose and amino acids from PN, as well as
- 124 energy from oral or enteral nutrition, has to be taken into account. Energy and lipid provided
- 125 from lipid-based medications should also be taken into account (e.g., propofol).
- 126 • Prior to administration of Intralipid, correct severe fluid and electrolyte disorders and
- 127 measure serum triglyceride levels to establish a baseline value. In patients with elevated
- 128 triglyceride levels, initiate Intralipid at a lower dosage and titrate in smaller increments,
- 129 monitoring the triglyceride levels with each adjustment [*see Warnings and Precautions*
- 130 (5.7)].

131 **Table 1: Recommended Pediatric and Adult Dosage and Infusion Rate**

Age	Nutritional Requirements	Direct Infusion Rate	
		Initial	Maximum
Birth to 2 years of age (including preterm and term neonates*) <i>[see Warnings and Precautions (5.1)]</i>	Initial 0.5 g/kg/day not to exceed 3 g/kg/day**	0.1 mL/kg/hour for the first 10 to 15 minutes; gradually increase to the required rate after 15 minutes	0.75 mL/kg/hour
Pediatric patients 2 to <12 years of age	Initial 1 to 2 g/kg/day not to exceed 2.5 g/kg/day***	0.2 to 0.4 mL/kg/hour for the first 10 to 15 minutes; gradually increase to the required rate after 15 minutes	0.75 mL/kg/hour
Pediatric patients 12 to 17 years of age	Initial 1 g/kg/day not to exceed 2 g/kg/day**	0.2 mL/kg/hour for the first 10 to 15 minutes; gradually increase to the required rate after 15 minutes	0.75 mL/kg/hour
Adults	1 g/kg/day in stable patients ≤1 g/kg/day in critically ill patients not to exceed 2.5 g/kg/day; not more than 500 mL of Intralipid should be infused on the first day of therapy**	0.2 mL/kg/hour for the first 10 to 15 minutes; gradually increase to the required rate after 30 minutes	0.5 mL/kg/hour

132 * The neonatal period is defined as including term, post-term, and preterm neonates. The neonatal
 133 period for term and post-term neonates is the day of birth plus 27 days. For preterm neonates, the
 134 neonatal period is defined as the day of birth through the expected age of delivery plus 27 days
 135 (i.e., 44 weeks post-menstrual age).

136 ** Daily dosage should also not exceed a maximum of 60% of total energy requirements *[see*
 137 *Overdosage (10)]*.

138
 139
 140
 141

142 Dosage Modifications in Patients with Essential Fatty Acid Deficiency

143 When Intralipid is administered to correct essential fatty acid deficiency (EFAD), supply 8% to
144 10% of caloric input from Intralipid in order to provide adequate amounts of linoleic and
145 linolenic acids.

146 **3 DOSAGE FORMS AND STRENGTHS**

147 Intralipid 20% is a sterile, homogenous, milky, white lipid injectable emulsion in Flexible
148 Containers supplied as:

- 149 • 20 g/100 mL (0.2 g/mL) of lipid in 100 mL single-dose Flexible Container
- 150 • 50 g /250 mL (0.2 g/mL) of lipid in 250 mL single-dose Flexible Container
- 151 • 100 g/500 mL (0.2 g/mL) of lipid in 500 mL single-dose Flexible Container
- 152 • 200 g /1,000 mL (0.2 g/mL) of lipid in 1,000 mL Pharmacy Bulk Package

153 **4 CONTRAINDICATIONS**

- 154 • Known hypersensitivity to egg, soybean, peanut, or any of the active or inactive ingredients
155 in Intralipid [*see Warnings and Precautions (5.3)*]
- 156 • Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum
157 triglyceride > 1,000 mg/dL) [*see Warnings and Precautions (5.7)*]

158 **5 WARNINGS AND PRECAUTIONS**

159 **5.1 Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsions in**
160 **Neonates and Infants**

161 In the postmarketing setting, serious adverse reactions including acute respiratory distress,
162 metabolic acidosis, and death have been reported in neonates and infants after rapid infusion of
163 intravenous lipid emulsions. Hypertriglyceridemia was commonly reported.

164 Strictly adhere to the recommended total daily dosage; the hourly infusion rate should not exceed
165 0.75 mL/kg/hour [*see Dosage and Administration (2.3)*].

166 Preterm and small for gestational age infants have poor clearance of intravenous lipid emulsion
167 and increased free fatty acid plasma levels following lipid emulsion infusion.

168 Carefully monitor the infant's ability to eliminate the infused lipids from the circulation (e.g.,
169 measure serum triglycerides and/or plasma free fatty acid levels). If signs or poor clearance of
170 lipids from the circulation occur, stop the infusion and initiate a medical evaluation [*see*
171 *Warnings and Precautions (5.5, 5.7) and Overdosage (10)*].

172 **5.2 Parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders**

173 Risk of Parenteral Nutrition-Associated Liver Disease

174 Parenteral nutrition-associated liver disease (PNALD), also referred to as intestinal failure-
175 associated liver disease (IFALD), can present as cholestasis or hepatic steatosis, and may

176 progress to steatohepatitis with fibrosis and cirrhosis (possibly leading to chronic hepatic
177 failure). The etiology of PNALD is multifactorial; however, intravenously administered
178 phytosterols (plant sterols) contained in plant-derived lipid emulsions, including Intralipid, have
179 been associated with development of PNALD.

180 In a randomized study of neonates and infants expected to be treated with PN for at least
181 28 days, parenteral nutrition-associated cholestasis (PNAC), a precursor to PNALD, developed
182 more frequently in Intralipid-treated patients than patients treated with a 4-oil mixed lipid
183 emulsion. [*see Adverse Reactions (6.1), Use in Specific Populations (8.4)*].

184 Monitor liver tests in patients treated with Intralipid and consider discontinuation or dosage
185 reduction if abnormalities occur.

186 Other Hepatobiliary Disorders

187 Hepatobiliary disorders including cholecystitis and cholelithiasis have developed in some PN-
188 treated patients without preexisting liver disease.

189 Monitor liver tests when administering Intralipid. Patients developing signs of hepatobiliary
190 disorders should be assessed early to determine whether these conditions are related to Intralipid
191 use.

192 **5.3 Hypersensitivity Reactions**

193 Intralipid contains soybean oil and egg phospholipids, which may cause hypersensitivity
194 reactions. Cross reactions have been observed between soybean and peanut. Intralipid is
195 contraindicated in patients with known hypersensitivity to egg, soybean, peanut or any of the
196 active or inactive ingredients in Intralipid. If a hypersensitivity reaction occurs, stop infusion of
197 Intralipid immediately and initiate appropriate treatment and supportive measures.

198 **5.4 Infections**

199 Parenteral nutrition, such as Intralipid, can support microbial growth and is an independent risk
200 factor for the development of catheter-related bloodstream infections. To decrease the risk of
201 infectious complications, ensure aseptic techniques are used for catheter placement, catheter
202 maintenance, and preparation and administration of Intralipid.

203 Monitor for signs and symptoms of infection including fever and chills, as well as laboratory test
204 results that might indicate infection (including leukocytosis and hyperglycemia). Perform
205 frequent checks of the intravenous catheter insertion site for edema, redness, and discharge.

206 **5.5 Fat Overload Syndrome**

207 Fat overload syndrome is a rare condition that has been reported with intravenous lipid injectable
208 emulsions and is characterized by a sudden deterioration in the patient's condition (e.g., fever,
209 anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, hepatomegaly,
210 deteriorating liver function, and central nervous system manifestations such as coma). A reduced
211 or limited ability to metabolize lipids, accompanied by prolonged plasma clearance (resulting in
212 higher lipid levels), may result in this syndrome. Although fat overload syndrome has been most

213 frequently observed when the recommended lipid dose or infusion rate was exceeded, cases have
214 also been described when the lipid formulation was administered according to instructions.

215 If signs or symptoms of fat overload syndrome occur, stop the infusion of Intralipid. The
216 syndrome is usually reversible when the infusion of the lipid emulsion is stopped.

217 **5.6 Refeeding Syndrome**

218 Administering PN to severely malnourished patients may result in refeeding syndrome, which is
219 characterized by the intracellular shift of potassium, phosphorus, and magnesium as patients
220 become anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these
221 complications, closely monitor severely malnourished patients and slowly increase their nutrient
222 intake.

223 **5.7 Hypertriglyceridemia**

224 The use of Intralipid is contraindicated in patients with hypertriglyceridemia with serum
225 triglyceride concentrations >1,000 mg/dL.

226 Patients with conditions such as inherited lipid disorders, obesity, diabetes mellitus, or metabolic
227 syndromes have a higher risk of developing hypertriglyceridemia with the use of Intralipid. In
228 addition, patients with hypertriglyceridemia may have worsening of their hypertriglyceridemia
229 with administration of Intralipid. Excessive dextrose administration may further increase such
230 risk.

231 Evaluate patients' capacity to metabolize and eliminate the infused lipid emulsion by measuring
232 serum triglycerides before the start of infusion (baseline value) and regularly throughout
233 treatment. If triglyceride levels are above 400 mg/dL in adults, stop the Intralipid infusion and
234 monitor serum triglyceride levels to avoid clinical consequences of hypertriglyceridemia such as
235 pancreatitis. In pediatric patients with hypertriglyceridemia, lower triglyceride levels (i.e., below
236 400 mg/dL) may be associated with adverse reactions. Monitor serum triglyceride levels to avoid
237 potential complications with hypertriglyceridemia such as pancreatitis, lipid pneumonitis, and
238 neurologic changes, including kernicterus.

239 To minimize the risk of new or worsening of hypertriglyceridemia, assess high-risk patients for
240 their overall energy intake including other sources of lipids and dextrose, as well as concomitant
241 drugs that may affect lipid and dextrose metabolism.

242 **5.8 Aluminum Toxicity**

243 Intralipid contains no more than 25 mcg/L of aluminum. Prolonged PN administration in patients
244 with renal impairment may result in aluminum reaching toxic levels. Preterm neonates are at
245 greater risk because their kidneys are immature, and they require large amounts of calcium and
246 phosphate solutions that contain aluminum.

247 Patients with impaired kidney function, including preterm neonates, who receive parenteral
248 levels of aluminum at greater than 4 to 5 mcg/kg/day can accumulate aluminum at levels

249 associated with central nervous system and bone toxicity. Tissue loading in these patients may
250 occur at even lower rates of administration.

251 **5.9 Monitoring/Laboratory Tests**

252 Monitor fluid status closely in patients with pulmonary edema or heart failure.

253
254 Throughout treatment, monitor serum triglycerides [*see Warnings and Precautions (5.7)*],
255 essential fatty acids, fluid and electrolyte status, serum osmolarity, blood glucose, liver and
256 kidney function, blood count (including platelets), and coagulation parameters.

257 The lipids contained in Intralipid may interfere with some laboratory tests (e.g., hemoglobin,
258 lactate dehydrogenase, bilirubin, oxygen saturation) if blood is sampled before lipids have
259 cleared from the bloodstream. Conduct these tests at least 6 hours after stopping the infusion.

260 Intralipid contains vitamin K that may counteract anticoagulant activity [*see Drug Interactions*
261 *(7)*].

262 **6 ADVERSE REACTIONS**

263 Adverse reactions described elsewhere in this Prescribing Information are:

- 264 • Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsion in Neonates
265 and Infants [*see Warnings and Precautions (5.1)*]
- 266 • Parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders [*see*
267 *Warnings and Precautions (5.2)*]
- 268 • Hypersensitivity Reactions [*see Warnings and Precautions (5.3)*]
- 269 • Infections [*see Warnings and Precautions (5.4)*]
- 270 • Fat Overload Syndrome [*see Warnings and Precautions (5.5)*]
- 271 • Refeeding Syndrome [*see Warnings and Precautions (5.6)*]
- 272 • Hypertriglyceridemia [*see Warnings and Precautions (5.7)*]
- 273 • Aluminum Toxicity [*see Warnings and Precautions (5.8)*]

274

275 **6.1 Clinical Trials Experience**

276 Because clinical trials are conducted under widely varying conditions, adverse reaction rates
277 observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of
278 another drug and may not reflect the rates observed in clinical practice.

279 Intralipid or equivalent soybean oil lipid emulsions functioned as the comparator in trials of the
280 4-oil mixed lipid emulsion [*see Clinical Studies (14)*]. The adverse reactions from these studies
281 are included to present the clinical experience with Intralipid.

282 The safety database for Intralipid or equivalent soybean oil lipid emulsion exposure in these
283 studies includes 393 patients (230 adults; 163 pediatric) in 9 clinical trials. Adult patients were
284 exposed for 5 days to 4 weeks in 5 clinical trials. Intralipid or equivalent soybean oil lipid
285 emulsion was used as a component of PN which also included dextrose, amino acids, vitamins,

286 and trace elements. Two of the 5 studies in adults were performed with Intralipid as a component
 287 of PN delivered in a 3-chamber bag.

288
 289 **Table 2: Adverse Reactions in >1% of Adult Patients Treated with Intralipid/Soybean oil**
 290 **emulsion**

Adverse Reaction	Number of Patients in Soybean Oil Lipid Emulsion Group (N=230)	Number of Patients in 4-Oil Mixed Lipid Emulsion Comparator Group (N=229)
Nausea	26 (11%)	20 (9%)
Vomiting	12 (5%)	15 (7%)
Pyrexia	11 (5%)	9 (4%)
Hypertension	9 (4%)	6 (3%)
Headache	7 (3%)	3 (1%)
Hyperglycemia	5 (2%)	12 (5%)
Abdominal pain	5 (2%)	8 (4%)
Flatulence	4 (2%)	10 (4%)
Blood triglycerides increased	4 (2%)	6 (3%)
Sepsis	4 (2%)	5 (2%)
Diarrhea	4 (2%)	3 (1%)
Pneumonia	4 (2%)	3 (1%)
Pruritus	4 (2%)	3 (1%)
Gamma-glutamyltransferase increased	4 (2%)	2 (1%)

291
 292 Less common adverse reactions occurring in ≤1% of adult patients who received Intralipid
 293 or equivalent soybean oil lipid emulsion were dyspepsia, urinary tract infection, anemia,
 294 infection, dyspnea, cholestasis, dysgeusia, increased blood alkaline phosphatase,
 295 tachycardia, liver function test abnormalities, dizziness, rash, and thrombophlebitis.

296 The 163 patients treated with Intralipid in four pediatric trials consisted of 147 patients <28 days
 297 of age, 9 patients 28 days to <2 years of age, and 7 patients 2 to 7 years of age; the duration of
 298 exposure was 7 to 84 days. Fifty-six percent of the pediatric patients were female, and 85% were
 299 Caucasian. Most pediatric patients were preterm neonates with feeding intolerance or other
 300 conditions requiring short-term (<29 days) PN.
 301

302

Table 3: Adverse Reactions in >1% of Pediatric Patients Treated with Intralipid

Adverse Reaction	Number of Patients in Intralipid Group (N=163)	Number of Patients in 4-Oil Mixed Lipid Emulsion Comparator Group (N=170)
Anemia	33 (20%)	30 (18%)
Vomiting	16 (10%)	16 (9%)
Gamma-glutamyltransferase increased	12 (7%)	10 (6%)
Cholestasis	10 (6%)	7 (4%)
Pyrexia	7 (4%)	7 (4%)
C-reactive protein increased	7 (4%)	6 (4%)
Hyperbilirubinemia	7 (4%)	5 (3%)
Bilirubin conjugated increased	7 (4%)	3 (2%)
Nosocomial infection	6 (4%)	10 (6%)
Blood alkaline phosphatase increased	6 (4%)	1 (1%)
Abdominal pain	5 (3%)	4 (2%)
Hematocrit decreased	5 (3%)	2 (1%)
Metabolic acidosis	5 (3%)	2 (1%)
Diarrhea	4 (3%)	3 (2%)
Tachycardia	4 (3%)	3 (2%)
Thrombocytopenia	4 (3%)	3 (2%)
Alanine aminotransferase increased	3 (2%)	1 (1%)
Aspartate aminotransferase increased	3 (2%)	0 (0%)
Parenteral nutrition-associated liver disease	3 (2%)	0 (0%)

303

304 Less common adverse reactions occurring in $\leq 1\%$ of pediatric patients who received Intralipid
 305 were hyperglycemia, sepsis, increased blood triglycerides, infection, fluid overload,
 306 hypertension, hypertriglyceridemia, rash, and hyperlipidemia.


307

308 In a randomized active-controlled, double-blind, parallel-group, multi-center study that
 309 included 152 neonates and 9 patients ranging in age from 29 to 153 days who were expected
 310 to require PN for at least 28 days, PNAC, a precursor to PNALD, developed more
 311 frequently in Intralipid-treated patients than in patients treated with a comparator 4-oil
 312 mixed lipid emulsion.

313 PNAC (defined as direct bilirubin >2 mg/dL with a second confirmed elevation >2 mg/dL at
 314 least 7 days later) occurred in 11.5% (9/78) in Intralipid-treated patients and 2.4% (2/83) of
 315 patients treated with a 4-oil mixed lipid emulsion. Most PNAC events occurred in patients
 316 who were treated for longer than 28 days.

317 The estimated cumulative incidence of PNAC is shown in the Kaplan-Meier cumulative
 318 incidence curve in Figure 1 [see *Pediatric Clinical Studies (14.2)*].

319 **Figure 1: Cumulative Incidence Curve of Time to Parenteral Nutrition-Associated**
 320 **Cholestasis (PNAC) with Standard Error Bars**



*There is increasing uncertainty in the estimate of the cumulative incidence as fewer patients are at risk.

321

322 6.2 Postmarketing Experience

323 The following adverse reactions from voluntary reports have been reported with Intralipid.
 324 Because many of these reactions were reported voluntarily from a population of uncertain size, it
 325 is not always possible to reliably estimate their frequency or establish a causal relationship to
 326 drug exposure.

327 *Cardiac disorders:* palpitations

328 *Gastrointestinal disorders:* vomiting, nausea

329 *General disorders and administration site conditions:* chills, chest discomfort, pyrexia

330 *Nervous system disorders:* dizziness

331 *Respiratory, thoracic, and mediastinal disorders:* dyspnea

332 *Immune system disorders:* hypersensitivity

333 *Vascular disorders:* phlebitis

334 *Blood and lymphatic system disorders:* hypercoagulability

335 **7 DRUG INTERACTIONS**

336 Soybean oil in Intralipid contains vitamin K₁ which may counteract the anticoagulant activity of
337 vitamin K antagonists such as warfarin. In patients who receive concomitant Intralipid and
338 warfarin, increase monitoring of laboratory parameters for anticoagulant activity.

339 **8 USE IN SPECIFIC POPULATIONS**

340 **8.1 Pregnancy**

341 Risk Summary

342 Administration of the recommended dose of Intralipid is not expected to cause major birth
343 defects, miscarriage, or other adverse maternal or fetal outcomes. No animal reproduction studies
344 have been conducted with Intralipid. There are risks to the fetus associated with severe
345 malnutrition during pregnancy (*see Clinical Considerations*).

346 The background risk of major birth defects and miscarriage for the indicated population(s) is
347 unknown. All pregnancies have a background risk of birth defect, loss, or other adverse
348 outcomes. In the U.S. general population, the estimated background risk of major birth defects
349 and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

350 Clinical Considerations

351 *Disease-Associated Maternal and/or Embryo-Fetal Risk*

352 Severe malnutrition in pregnant women is associated with preterm delivery, low birth weight,
353 intrauterine growth restriction, congenital malformations, and perinatal mortality. Parenteral
354 nutrition should be considered if the pregnant woman's nutritional requirements cannot be
355 fulfilled by oral or enteral intake.

356 **8.2 Lactation**

357 Risk Summary

358 Administration of the recommended dose of Intralipid is not expected to cause harm to a
359 breastfed infant. There are no data on the presence of Intralipid in human or animal milk or its
360 effects on milk production. Available published literature includes fewer than five reported cases
361 of breastfed infants exposed to various lipid emulsions via lactation, and these cases did not
362 report adverse events. The developmental and health benefits of breastfeeding should be
363 considered along with the mother's clinical need for Intralipid and any potential adverse effects
364 of Intralipid on the breastfed infant, or from the underlying maternal condition.

365 **8.4 Pediatric Use**

366 Intralipid is contraindicated in pediatric patients with severe disorders of lipid metabolism [*see*
367 *Contraindications (4)*].

368 The safety and effectiveness of Intralipid have been established as a source of calories and
369 essential fatty acids for PN in pediatric patients, including term and preterm neonates. Use of
370 Intralipid in neonates is supported by evidence from short-term (i.e., 1- to 4- week) studies, and
371 one study following neonates beyond 4 weeks [*see Clinical Studies (14.2)*]. Use of Intralipid in

372 older pediatric patients is supported by evidence from short-term (i.e., <28 days) studies in
373 pediatric patients 28 days to 12 years of age and additional evidence from studies in adults [*see*
374 *Clinical Studies (14)*]. The most common adverse reactions in Intralipid-treated pediatric patients
375 were anemia, vomiting, gamma-glutamyltransferase increased, and cholestasis. PNAC, a
376 precursor to PNALD, developed more frequently in Intralipid-treated patients than in patients
377 treated with a comparator 4-oil mixed lipid emulsion [*see Warnings and Precautions (5.1) and*
378 *Adverse Reactions (6.1)*].

379 In the postmarketing setting, clinical decompensation with rapid infusion of intravenous lipid
380 emulsion in neonates and infants, sometimes fatal, has been reported [*see Warnings and*
381 *Precautions (5.1)*]. Because of immature renal function, preterm neonates receiving prolonged
382 treatment with Intralipid may be at risk for aluminum toxicity [*see Warnings and Precautions*
383 *(5.8)*].

384 **8.5 Geriatric Use**

385 Reported clinical experience has not identified differences in responses between the elderly and
386 younger patients. In general, dose selection for an elderly patient should be cautious, usually
387 starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic,
388 renal, or cardiac function, and of concomitant disease or drug therapy.

389 **10 OVERDOSAGE**

390 In the event of an overdose, serious adverse reactions may result [*see Warnings and Precautions*
391 *(5.1, 5.5)*]. Stop the infusion of Intralipid until triglyceride levels have normalized and symptoms
392 have abated. The effects are usually reversible by stopping the lipid infusion. If medically
393 appropriate, further intervention may be indicated. Lipids are not dialyzable from plasma.


394 **11 DESCRIPTION**

395 Intralipid is a sterile, non-pyrogenic, white, homogenous lipid emulsion for intravenous infusion
396 as a source of calories and essential fatty acids. The lipid content of Intralipid is 0.2 g/mL and
397 comprises soybean oil. The phosphate content is 15 mmol/L.

398 The total energy content, including fat, phospholipids, and glycerin is 2,000 kcal/L.

399 Each 100 mL of Intralipid contains approximately 20 g soybean oil, 1.2 g egg yolk phospholipids,
400 2.25 g glycerin, water for injection, and sodium hydroxide for pH adjustment (pH 6 to 8.9).
401 Intralipid has an osmolality of approximately 350 mOsmol/kg water (which represents an
402 osmolarity of 260 mOsmol/L).

403 The soybean oil is a refined natural product consisting of a mixture of neutral triglycerides of
404 predominantly unsaturated fatty acids with the following structure:



405


406 where $\text{R}_1\text{C}-$, $\text{R}_2\text{C}-$ and $\text{R}_3\text{C}-$ are saturated and unsaturated fatty acid residues.

407 The major component fatty acids in Intralipid are linoleic acid (44% to 62%), oleic acid (19% to
 408 30%), palmitic acid (7% to 14%), alpha-linolenic acid (4% to 11%), and stearic acid (1.4% to
 409 5.5%). These fatty acids have the following chemical and structural formulas:

Linoleic Acid $\text{C}_{18}\text{H}_{32}\text{O}_2$	
Oleic Acid $\text{C}_{18}\text{H}_{34}\text{O}_2$	
Palmitic Acid $\text{C}_{16}\text{H}_{32}\text{O}_2$	
α-Linolenic Acid $\text{C}_{18}\text{H}_{30}\text{O}_2$	
Stearic Acid $\text{C}_{18}\text{H}_{36}\text{O}_2$	

410 Purified egg phosphatides are a mixture of naturally occurring phospholipids which are isolated
 411 from the egg yolk. These phospholipids have the following general structure:


412




413

414

415 $\text{R}_1\text{C}-$ and $\text{R}_2\text{C}-$ contain saturated and unsaturated fatty acids that abound in neutral fats. R_3 is
 416 primarily either the choline or ethanolamine ester of phosphoric acid.




Phosphatidylcholine



Phosphatidylethanolamine

417

418 Glycerin is chemically designated C₃H₈O₃ and is a clear colorless, hygroscopic syrupy liquid. It
 419 has the following structural formula:



420

421 The container-solution unit is a closed system and is not dependent upon entry of external air
 422 during administration. The container is overwrapped to provide protection from the physical
 423 environment and to provide an additional oxygen and moisture barrier when necessary.

424 Intralipid contains no more than 25 mcg/L of aluminum.

425 The container is not made with natural rubber latex, PVC, or DEHP.

426 12 CLINICAL PHARMACOLOGY

427 12.1 Mechanism of Action

428 Intralipid provides a biologically utilizable source of calories and essential fatty acids.

429 Fatty acids serve as an important substrate for energy production. The most common mechanism
 430 of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids
 431 are also important for membrane structure and function, as precursors for bioactive molecules
 432 (such as prostaglandins), and as regulators of gene expression.

433 12.2 Pharmacodynamics

434 The pharmacodynamic effects of Intralipid have not been fully characterized.

435 12.3 Pharmacokinetics

436 Intralipid provides fatty acids in the form of triglycerides which are hydrolyzed by lipoprotein
 437 lipase to release free fatty acids. Linoleic acid and alpha-linolenic acid are metabolized within a
 438 common biochemical pathway through a series of desaturation and elongation steps.

439 **13 NONCLINICAL TOXICOLOGY**

440 **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

441 Carcinogenicity, genetic toxicology, and animal fertility studies have not been performed with
442 Intralipid.

443 **14 CLINICAL STUDIES**

444 Intralipid or equivalent soybean oil lipid emulsion functioned as the comparator for the 4-oil
445 mixed lipid emulsion in the clinical studies described in sections 14.1 and 14.2. The trial results
446 are included to present the clinical experience with Intralipid.

447 **14.1 Adult Clinical Studies**

448 The efficacy of Intralipid or equivalent soybean oil lipid emulsion compared to a 4-oil mixed
449 lipid emulsion was evaluated in 3 clinical studies in adult patients. Nutritional efficacy in adult
450 studies was assessed by changes in anthropometric indices (body weight, height, and body mass
451 index [BMI]), changes in lipid and protein metabolism (albumin), and fatty acid parameters. Of
452 the 354 adult patients (178 Intralipid; 176 comparator), 62% were male, 99% were Caucasian,
453 and ages ranged from 19 to 96 years. All patients received Intralipid/equivalent soybean oil lipid
454 emulsion or the comparator as part of a PN regimen. Although Adult Study 1, Adult Study 2, and
455 Adult Study 3 were not designed for formal statistical comparisons between Intralipid/equivalent
456 soybean oil lipid emulsion and the comparator, they support Intralipid as a source of calories and
457 essential fatty acids in adults. The lipid dosage was variable in these studies and adjusted to the
458 patient's nutritional requirements.

459 Adult Study 1 was a double-blind, randomized, active-controlled, parallel-group, multicenter
460 study in patients who required PN for at least 28 days. Seventy-five patients were enrolled, and
461 73 patients were treated with either Intralipid or the comparator. Changes in mean triglyceride
462 levels from baseline values to Week 4 were similar in both the Intralipid and comparator groups.
463 Mean albumin levels demonstrated a comparable decrease in both groups. Mean changes in body
464 weight (kg) and BMI (kg/m²) were similar in both the Intralipid and the comparator groups.

465 Adult Study 2 was a phase 3, randomized, double-blind, active-controlled, multicenter study. A
466 total of 249 postoperative adult patients were randomized to receive either an equivalent soybean
467 oil lipid emulsion to Intralipid or the comparator for at least 5 days as part of their total
468 parenteral nutrition (TPN) regimen. From baseline to Day 6, mean triglyceride levels increased
469 similarly in both the soybean oil lipid emulsion and the comparator groups.

470 Adult Study 3 was a double-blind randomized, active-controlled, parallel-group, single-center
471 study in 32 adult patients who required TPN for 10 to 14 days. Patients were treated with either
472 an equivalent soybean oil lipid emulsion to Intralipid or the comparator. The increase in mean
473 triglyceride levels from baseline to the final assessment was similar in both the soybean oil lipid
474 emulsion and the comparator groups.

475 **14.2 Pediatric Clinical Studies**

476 The efficacy of Intralipid compared to a 4-oil mixed lipid emulsion in pediatric patients of all age
 477 groups, including term and preterm neonates, was evaluated in 333 patients in 4 randomized
 478 active-controlled, double-blind, parallel-group controlled clinical studies. Although Pediatric
 479 Studies 1, 2, 3, and 4 were not designed for formal statistical comparisons between Intralipid and
 480 the comparator, they support Intralipid as a source of calories and essential fatty acids in
 481 pediatric patients. The 333 pediatric patients (163 Intralipid; 170 comparator) consisted of 296
 482 patients who were <28 days old, 22 patients 29 days to <2 years old, and 15 patients 2 to <12
 483 years old. Fifty percent of the pediatric patients were male and 87% were Caucasian. All patients
 484 received Intralipid or the comparator as part of a PN regimen. Nutritional efficacy in neonates
 485 was assessed by changes in anthropometric indices (body weight, height, head circumference).
 486 Nutritional efficacy in pediatric patients, 28 days to 12 years of age, was assessed by changes in
 487 triglyceride concentrations and fatty acid parameters.

488 Pediatric Study 1 enrolled 152 preterm and term neonates (birth up to 28 days) and 9 patients
 489 ranging in age from 29 to 153 days. Patients were treated with either Intralipid (n=78) or the
 490 comparator (n=83). A total of 119 patients (58 Intralipid; 61 comparator) received study
 491 treatment for ≥14 days. A total of 27 patients received Intralipid for ≥29 days; 5 patients received
 492 Intralipid for the maximum study duration of 78-84 days.

493 Pediatric Studies 2 and 3 enrolled 60 and 84 preterm neonates, respectively, who were treated
 494 with either Intralipid or the comparator (72 neonates in each group). The median treatment
 495 duration for Intralipid group was 9 days in Pediatric Study 2 and 6 days in Pediatric Study 3.

496 Pediatric Study 4 enrolled 13 patients 5 months to <2 years of age and 15 patients 2 to 11.5 years
 497 of age. Patients were treated with either Intralipid (n=13) or the comparator (n=15) with a
 498 median treatment duration of 27 days.

499 In Pediatric Studies 1, 2 and 3, which enrolled neonates, Intralipid-treated patients showed
 500 increases in the median body weight, height/length, and head circumference (which was
 501 measured in Studies 1 and 3) comparable to the comparator-treated patients. Mean triglyceride
 502 levels from baseline to the final assessment in Pediatric Studies 1, 2, and 3 were variable in these
 503 neonates, but overall differences between groups were not considered clinically relevant. Mean
 504 triglyceride levels in Pediatric Study 4 were variable but remained within the normal range.

505 **16 HOW SUPPLIED/STORAGE AND HANDLING**

506 Intralipid 20% (lipid injectable emulsion, USP) is a sterile, homogeneous, milky, white lipid
 507 emulsion supplied in Flexible Containers as follows:

Product Code	Unit of Use	Unit of Sale
831800311	NDC 65219-531-01 One 100 mL freeflex [®] bag	NDC 65219-531-10 Package of 10 freeflex [®] bags
831818311	NDC 65219-533-01 One 250 mL freeflex [®] bag	NDC 65219-533-25 Package of 10 freeflex [®] bags
831826311	NDC 65219-535-01 One 500 mL freeflex [®] bag	NDC 65219-535-50 Package of 12 freeflex [®] bags

Intralipid® 20% is also available as Pharmacy Bulk Package in the following fill size.

Product Code	Unit of Use	Unit of Sale
831842311	NDC 65219-539-01 One 1000 mL freeflex ® bag	NDC 65219-539-10 Package of 6 freeflex ® bags

508

509 Store below 25°C (77°F). Avoid excessive heat. Do not freeze. If accidentally frozen,
510 discard container. Store in the overpouch until ready for use.

511 Intralipid 100 mL, 250 mL and 500 mL single-dose Flexible Containers

512 After removing the overpouch, infuse immediately. If not used immediately, the product
513 should be stored at 2°C to 8°C (36°F to 46°F) for no longer than 24 hours. After removal
514 from storage, infuse within 12 hours when using a Y-connector or within 24 hours if used as
515 part of an admixture [see *Dosage and Administration (2.2)*].

516 Intralipid 1,000 mL Pharmacy Bulk Package

517 Use the Pharmacy Bulk Package immediately for admixing after removal from the
518 overpouch. If not used immediately, the product should be stored for no longer than 24
519 hours at 2°C to 8°C (36°F to 46°F). After removal from storage, and once the closure is
520 penetrated, use Pharmacy Bulk Package contents within 4 hours [see *Dosage and*
521 *Administration (2.2)*].

522 Admixtures

523 Infuse admixtures containing Intralipid immediately. If not used immediately, admixtures
524 should be stored at 2°C to 8°C (36°F to 46°F) for no longer than 24 hours. After removal
525 from storage, infuse within 24 hours [see *Dosage and Administration (2.2)*].

526 Protect the admixed PN solution from light [see *Dosage and Administration (2.2)*].

527 **17 PATIENT COUNSELING INFORMATION**

528 When initiating Intralipid administration, discuss the following information with the patient or
529 caregiver:

530 Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsion in Neonates and
531 Infants

532 Inform caregivers that acute respiratory distress and death may occur in neonates and infants
533 after rapid infusion of intravenous lipid emulsions. If Intralipid is infused at home, instruct
534 caregivers not to exceed the maximum infusion rate [see *Warnings and Precautions (5.1)*].

535 Parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders

536 Inform patients and caregivers that use of parenteral nutrition may result in parenteral nutrition-
537 associated liver disease and/or other hepatobiliary disorders [see *Warnings and Precautions*

538 (5.2)].

539 Hypersensitivity Reactions

540 Inform patients and caregivers that Intralipid may cause hypersensitivity reactions. If Intralipid
541 is infused at home, instruct patients or caregivers to stop the infusion of Intralipid immediately
542 and seek medical attention if a hypersensitivity reaction occurs, [see *Warnings and Precautions*
543 (5.3)].

544 Infections

545 Inform patients and caregivers that patients who receive Intralipid are at risk of infection. If
546 Intralipid is infused at home, instruct patients or caregivers to ensure aseptic techniques are used
547 for the preparation and administration of Intralipid and to monitor for signs and symptoms of
548 infection [see *Warnings and Precautions* (5.4)].

549 Fat Overload Syndrome

550 Inform patients and caregivers that fat overload syndrome has been reported with the use of
551 intravenous lipid emulsions. If Intralipid is infused at home, instruct patients or caregivers to
552 stop the infusion of Intralipid if signs or symptoms of fat overload syndrome occur [see
553 *Warnings and Precautions* (5.5)].

554 Refeeding Syndrome

555 If the patient is severely malnourished, inform patients and caregivers that administering
556 parenteral nutrition including Intralipid may result in refeeding syndrome [see *Warnings and*
557 *Precautions* (5.6)].

558 Hypertriglyceridemia

559 Inform patients and their caregivers about the risks of hypertriglyceridemia with Intralipid use
560 [see *Warnings and Precautions* (5.7)].

561 Aluminum Toxicity

562 Inform patients and their caregivers that prolonged PN administration in patients with renal
563 impairment, including preterm neonates, may result in aluminum reaching toxic levels
564 associated with central nervous system and bone toxicity [see *Warnings and Precautions*
565 (5.8)].

566 Preparation and Administration Instructions

567 If it is acceptable for a patient or caregiver to administer Intralipid at home, then provide
568 recommendations on how to inspect and prepare, add compatible additives (when
569 appropriate), administer, and store Intralipid [see *Dosage and Administration* (2.1, 2.2)].
570 Inform patients or caregivers not to deviate from the administration instructions given by the
571 healthcare provider.

572

572 Manufactured by:



576 Uppsala, Sweden

577 Intralipid® is a registered trademark of Fresenius Kabi AB.

578 www.fresenius-kabi.com/us

579 451713A

580

581

582

583

584

585

Intralipid[®] 30% (A 30% I.V. Fat Emulsion)


Pharmacy Bulk Package
Not for Direct Infusion

DESCRIPTION

Intralipid[®] 30% (A 30% I.V. Fat Emulsion) Pharmacy Bulk Package is a sterile, non-pyrogenic fat emulsion intended as a source of calories and essential fatty acids for use in a pharmacy admixture program. It is made up of 30% Soybean Oil, 1.2% Egg Yolk Phospholipids, 1.7% Glycerin, and Water for Injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8. pH range is 6 to 8.9.


Intralipid 30% Pharmacy Bulk Package is not intended for direct infusion. It is a sterile dosage form which contains several single doses for use in the preparation of three-in-one or total nutrient admixtures (TNAs) in a pharmacy admixture program.

The soybean oil is a refined natural product consisting of a mixture of neutral triglycerides of predominantly unsaturated fatty acids with the following structure:




where $\text{R}_1\text{C}-$, $\text{R}_2\text{C}-$ and $\text{R}_3\text{C}-$ are saturated and unsaturated fatty acid residues.


The major component fatty acids are linoleic acid (44-62%), oleic acid (19-30%), palmitic acid (7-14%), α -linolenic acid (4-11%) and stearic acid (1.4-5.5%)¹. These fatty acids have the following chemical and structural formulas:




Purified egg phosphatides are a mixture of naturally occurring phospholipids which are isolated from the egg yolk. These phospholipids have the following general structure:



$\text{R}_1\text{C}-$ and $\text{R}_2\text{C}-$ contain saturated and unsaturated fatty acids that abound in neutral fats. R_3 is primarily either the choline or ethanolamine ester of phosphoric acid.




Phosphatidylcholine



Phosphatidylethanolamine

Glycerin is chemically designated $\text{C}_3\text{H}_8\text{O}_3$ and is a clear colorless, hygroscopic syrupy liquid. It has the following structural formula:



Intralipid 30% (A 30% I.V. Fat Emulsion) has an osmolality of approximately 310 mOsmol/kg water (which represents 200 mOsmol/L of emulsion) and contains emulsified fat particles of approximately 0.5 micron size.

The total caloric value, including fat, phospholipid and glycerin, is 3.0 kcal per mL of Intralipid 30%. The phospholipids present contribute 47 milligrams or approximately 1.5 mmol of phosphorus per 100 mL of the emulsion.

The primary plastic container (Biofine™) is made from multilayered film specifically designed for parenteral nutrition drug products. The film is polypropylene based comprising three co-extruded layers. It contains no plasticizers and exhibits virtually no leachables. The container does not contain DEHP (di(2-ethylhexyl) phthalate) or PVC. This product is not made with natural rubber latex. The container is nontoxic and biologically inert.

The container-emulsion unit is a closed system and is not dependent upon entry of external air during administration.

The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

CLINICAL PHARMACOLOGY

Intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. The infused fat particles are cleared from the blood stream in a manner thought to be comparable to the clearing of chylomicrons.

Intralipid will prevent the biochemical lesions of essential fatty acid deficiency (EFAD) and correct the clinical manifestations of the EFAD syndrome.

INDICATIONS AND USAGE

Intralipid® 30% Pharmacy Bulk Package is indicated for use in a pharmacy admixture program for the preparation of three-in-one or total nutrient admixtures (TNAs) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of EFAD.

CONTRAINDICATIONS

Intralipid is contraindicated in patients with:

- Disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia.
- Known hypersensitivity to egg, soybean, peanut or any of the active ingredients or excipients in Intralipid 30%.

INTRALIPID 30% PHARMACY BULK PACKAGE IS NOT INTENDED FOR DIRECT INTRAVENOUS ADMINISTRATION. DILUTING INTRALIPID 30% TO A 10% OR 20% CONCENTRATION WITH AN INTRAVENOUS FLUID SUCH AS NORMAL SALINE OR OTHER DILUENT DOES NOT PRODUCE A DILUTION THAT IS EQUIVALENT IN COMPOSITION TO INTRALIPID 10% OR 20% I.V. FAT EMULSIONS, AND SUCH A DILUTION SHOULD NOT BE GIVEN BY DIRECT INTRAVENOUS ADMINISTRATION (FOR EXAMPLE, THROUGH A Y-CONNECTOR).

WARNINGS

Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsions in Neonates and Infants

In the postmarketing setting, serious adverse reactions including acute respiratory distress, metabolic acidosis, and death have been reported in neonates and infants after rapid infusion of intravenous lipid emulsions. Hypertriglyceridemia was commonly reported.

Strictly adhere to the recommended total daily dosage; the hourly infusion rate should not exceed 0.5 mL/kg/hour. (see DOSAGE AND ADMINISTRATION section)

Preterm and small for gestational age infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.

Carefully monitor the infant's ability to eliminate the infused lipids from the circulation (e.g., measure serum triglycerides and/or plasma free fatty acid levels). If signs or poor clearance of lipids from the circulation occur, stop the infusion and initiate a medical evaluation. (see PRECAUTIONS and OVERDOSAGE sections)

Parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders

Risk of Parenteral Nutrition-Associated Liver Disease


Parenteral nutrition-associated liver disease (PNALD), also referred to as intestinal failure-associated liver disease (IFALD), can present as cholestasis or hepatic steatosis, and may progress to steatohepatitis with fibrosis and cirrhosis (possibly leading to chronic hepatic failure). The etiology of PNALD is multifactorial; however, intravenously administered phytosterols (plant sterols) contained in plant-derived lipid emulsions, including Intralipid, have been associated with development of PNALD.

In a randomized active-controlled, double-blind, parallel-group, multi-center study that included 152 neonates and 9 patients ranging in age from 29 to 153 days who were expected to require PN for at least 28 days, parenteral nutrition-associated cholestasis (PNAC), a precursor to PNALD, developed more frequently in Intralipid-treated patients than in patients treated with a 4-oil mixed lipid emulsion.

PNAC (defined as direct bilirubin >2mg/dl with a second confirmed elevation >2mg/dl at least 7 days later) occurred in 11.5% (9/78) in Intralipid-treated patients and 2.4% (2/83) of patients treated with a 4-oil mixed lipid emulsion. Most PNAC events occurred in patients who were treated for longer than 28 days.

The estimated cumulative incidence of PNAC is shown in the Kaplan-Meier cumulative incidence curve in Figure 1.

Figure 1: Cumulative Incidence Curve of Time to Parenteral Nutrition-Associated Cholestasis (PNAC) with Standard Error Bars



*There is increasing uncertainty in the estimate of the cumulative incidence as fewer patients are at risk.

Monitor liver tests in patients treated with Intralipid and consider discontinuation or dosage reduction if abnormalities occur.

Other Hepatobiliary Disorders

Hepatobiliary disorders including cholecystitis and cholelithiasis have developed in some PN-treated patients without preexisting liver disease.

Monitor liver tests when administering Intralipid. Patients developing signs of

hepatobiliary disorders should be assessed early to determine whether these conditions are related to Intralipid use.

Aluminum Toxicity

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS

When Intralipid 30% is administered, the patient's capacity to eliminate the infused fat from the circulation must be monitored by use of an appropriate laboratory determination of serum triglycerides. Overdosage must be avoided.

During intravenous administration with Intralipid 30%, perform liver tests to monitor for PNALD. If patients develop liver test abnormalities, consider discontinuation of Intralipid or dosage reduction. (See WARNINGS section)

Frequent platelet counts should be done in neonatal patients receiving parenteral nutrition with Intralipid 30%.

Drug product contains no more than 25 mcg/L of aluminum.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Studies with Intralipid have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

Pregnancy: Animal reproduction studies have not been conducted with Intralipid. It is also not known whether Intralipid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Intralipid should be given to a pregnant woman only if clearly needed.

Nursing Mothers: Caution should be exercised when Intralipid is administered to a nursing woman.

Pediatric Use: See DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS

The adverse reactions observed can be separated into two classes:

1. Those more frequently encountered are due either to a) contamination of the intravenous catheter and result in sepsis, or to b) vein irritation by concurrently infused hypertonic solutions and may result in thrombophlebitis. These adverse reactions are inseparable from the hyperalimentation procedure with or without Intralipid.
2. Less frequent reactions more directly related to Intralipid are: a) immediate or early adverse reactions, each of which has been reported to occur in clinical trials, in an incidence of less than 1%; dyspnea, cyanosis, allergic reactions, hyperlipemia, hypercoagulability, nausea, vomiting, headache, flushing, increase in temperature, sweating, sleepiness, pain in the chest and back, slight pressure over the eyes, dizziness,

and irritation at the site of infusion, and, rarely, thrombocytopenia in neonates; b) delayed adverse reactions such as hepatomegaly, jaundice due to central lobular cholestasis, splenomegaly, thrombocytopenia, leukopenia, transient increases in liver tests, and overloading syndrome (focal seizures, fever, leukocytosis, hepatomegaly, splenomegaly and shock).

The deposition of a brown pigmentation in the reticuloendothelial system, the so-called “intravenous fat pigment,” has been reported in patients infused with Intralipid. The causes and significance of this phenomenon are unknown.

OVERDOSAGE

In the event of overdose, serious adverse reactions may result. Stop the infusion containing Intralipid 30% (A 30% I.V. Fat Emulsion) until visual inspection of the plasma, determination of triglyceride concentrations, or measurement of plasma light-scattering activity by nephelometry indicates the lipid has cleared. Re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS.

DOSAGE AND ADMINISTRATION

Intralipid 30% (A 30% I.V. Fat Emulsion) Pharmacy Bulk Package should be administered only as a part of a three-in-one or total nutrient admixture via peripheral vein or by central venous infusion.

The recommended nutritional requirements of fat and recommended dosages of Intralipid to be administered to meet those requirements for adults and pediatric patients are provided below, along with recommendations for the initial and maximum infusion rates. Do not exceed the recommended maximum infusion rate.

Directions For Proper Use of Pharmacy Bulk Package

INTRALIPID 30% (A 30% I.V. Fat Emulsion) PHARMACY BULK PACKAGE IS NOT INTENDED FOR DIRECT INFUSION. The container closure may be penetrated only once using a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Once the closure is penetrated, the contents should be dispensed as soon as possible; the transfer of contents to suitable TPN admixture containers must be completed within 4 hours of closure penetration. The bag should be stored below 25°C (77°F) after the closure has been entered.

Admixtures made using Intralipid 30% should be used promptly.

See MIXING GUIDELINES AND LIMITATIONS section for admixture storage recommendations.

Adult Patients

The initial infusion rate of the nutrient admixture in adults should be the equivalent of 0.1 g fat/minute for the first 15 to 30 minutes of infusion. If no untoward reactions occur (see ADVERSE REACTIONS section), the infusion rate of the nutrient admixture can be increased to be equivalent to 0.2 g fat/minute. For adults, the admixture should not contain more than 330 mL of Intralipid 30% on the first day of therapy. If the patient has no untoward reactions, the dose can be increased on the following day. The daily dosage should not exceed 2.5 g of fat/kg of body weight (8.3 mL of Intralipid 30% per kg). Intralipid 30% should make up no more than 60% of the total caloric input to the patient. Maximum infusion rate should not exceed 0.1 g/kg/hr.

Carbohydrate and a source of amino acids should comprise the remaining caloric input. Maximum infusion rate should not exceed 0.1 g/kg/hr.

Pediatric Patients

The dosage for premature infants starts at 0.5 g fat/kg body weight/24 hours (1.7 mL) Intralipid 30% and may be increased in relation to the infant's ability to eliminate fat. The maximum recommended dosage is 3 g fat/kg/24 hours.

Pediatric patients may be at risk for parenteral nutrition-associated liver disease (PNALD), also known as intestinal failure-associated liver disease (see WARNINGS section) when receiving Intralipid for durations exceeding two weeks. During intravenous administration of Intralipid 30%, perform liver tests to monitor for PNALD.

The initial rate of infusion of the nutrient admixture in older pediatric patients should be no more than 0.01 g fat/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.1 g of fat/kg/hour. The daily dosage should not exceed 3 g of fat/kg of body weight³. Intralipid (equivalent to 0.125 g/kg/hour) should make up no more than 60% of the total caloric input to the patient. Carbohydrate and a source of amino acids should comprise the remaining caloric input.

Essential Fatty Acid Deficiency

When Intralipid 30% is administered to correct essential fatty acid deficiency, eight to ten percent of the caloric input should be supplied by Intralipid 30% in order to provide adequate amounts of linoleic and linolenic acids. When EFAD occurs together with stress, the amount of Intralipid 30% needed to correct the deficiency may be increased.

Administration

See MIXING GUIDELINES AND LIMITATIONS section for information regarding mixing this fat emulsion with other parenteral fluids.

INTRALIPID 30% (A 30% I.V. Fat Emulsion) is not for direct infusion. It must be infused as part of an admixture into a central or peripheral vein. The flow rate of the admixture should be controlled with an infusion pump. Use a 1.2-micron filter with admixtures containing Intralipid 30%. Filters of less than 1.2-micron pore size must not be used. Conventional administration sets and TPN pooling bags contain polyvinyl chloride (PVC) components that have DEHP (di(2-ethylhexyl) phthalate) as a plasticizer. Fat-containing fluids such as Intralipid extract DEHP from these PVC components. Therefore, it may be advisable to use a non-DEHP administration set for infusing admixtures which contain Intralipid. Do not use any bag in which there appears to be an oiling out on the surface of the emulsion. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

MIXING GUIDELINES AND LIMITATIONS

INTRALIPID 30% PHARMACY BULK PACKAGE IS NOT INTENDED FOR DIRECT INFUSION. It must be combined with total parenteral nutrition (TPN) fluids so that the resulting admixture has a final concentration of not more than 20% fat (0.2 g fat per mL of admixture). The following table may be used as guide:

Volume of Intralipid 30%		Required Minimum Volume of Dextrose /Amino Acid Solutions		Final Volume of Admixture	Final Fat Concentration
1 mL	+	0.5 mL	=	1.5 mL	20%
100 mL	+	50 mL	=	150 mL	20%

250 mL	+	125 mL	=	375 mL	20%
500 mL	+	250 mL	=	750 mL	20%

Because of the potential for life threatening events, caution should be taken to ensure that precipitates have not formed in any parenteral nutrition mixture. Perform all manipulations in a suitable work area, such as laminar flow hood.

Failure to follow the Mixing Guideline and Limitations below, including recommended storage temperature, storage time, order of mixing, etc. may result in an unsuitable admixture.

Intralipid 30% (A 30% I.V. Fat Emulsion) may be mixed with Amino Acid and Dextrose Injections where compatibility have been demonstrated. Additives known to be incompatible should not be used. Please consult with pharmacist. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives (e.g., Vitamins and Minerals).

Protect the admixed PN solution from light.

When being mixed the following proper mixing sequence must be followed to minimize pH related problems by ensuring that typically acidic Dextrose Injections are not mixed with lipid emulsions alone:

1. Transfer Dextrose Injection to the TPN Admixture Container
2. Transfer Amino Acid Injection
3. Transfer Intralipid 30% (A 30% I.V. Fat Emulsion)

Note: Amino Acid Injection, Dextrose Injection and Intralipid may be simultaneously transferred to the admixture container. Admixing should be accompanied by gentle agitation to avoid localized concentration effects.

Additives must not be added directly to Intralipid and in no case should Intralipid be added to the TPN container first. Bags should be shaken gently after each addition to minimize localized concentration.

If the admixture is not used immediately, the in-use storage time and conditions prior to use are the responsibility of the user and should normally not be longer than 24 hours at 2-8°C. After removal from storage at 2-8°C, the admixture should be infused within 24 hours.

It is essential that the admixture be prepared using strict aseptic techniques as this nutrient mixture is a good growth medium for microorganisms.

Supplemental electrolytes, trace metals or multivitamins may be required in accordance with the prescription of the attending physician.

The prime destabilizers of emulsions are excessive acidity (low pH) and inappropriate electrolyte content. Careful consideration should be given to additions of divalent cations (Ca^{++} and Mg^{++}) which have been shown to cause emulsion instability. Amino acid solutions exert a buffering effect protecting the emulsion. The admixture should be inspected carefully for “breaking or oiling out” of the emulsion. “Breaking or oiling out” is described as the separation of the emulsion and can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion. The admixture should also be examined for particulates. The admixture must be discarded if

any of the above is observed.

HOW SUPPLIED

Intralipid 30% (A 30% I.V. Fat Emulsion) is supplied as a sterile emulsion in Pharmacy Bulk Package in the following sizes.

Product Code	Unit of Use	Unit of Sale
831834311	NDC 65219-537-01 One 500 mL freeflex [®] bag	NDC 65219-537-50 Package of 12 freeflex [®] bags

STORAGE

Intralipid 30% should not be stored above 25°C (77°F). Do not freeze Intralipid 30%. If accidentally frozen, discard the bag.

REFERENCES

1. Padley FB: "Major Vegetable Fats", The Lipid Handbook (Gunstone FD, Harwood JL, Padley FB, eds.), Chapman and Hall Ltd., Cambridge, UK (1986), pp. 88-9.
2. Levene MI, Wigglesworth JS, Desai R: Pulmonary fat accumulation after Intralipid infusion in the preterm infant. Lancet 1980; 2(8199):815-8.
3. American Academy of Pediatrics: Use of intravenous fat emulsion in pediatric patients. Pediatrics 1981; 68:5(Nov) 738-43.

Revised: May 2023

Manufactured by:




Uppsala, Sweden

Intralipid[®] is a registered trademark of Fresenius Kabi AB.

www.fresenius-kabi.com/us
451715A


Instruction for Use - Intralipid 30% Pharmacy Bulk Package Container

1.




1. The integrity indicator (Oxalert™) A should be inspected before removing the overwrap. If the indicator is black the overwrap is damaged and the product should be discarded.

2.



2. Remove the overwrap by tearing at the notch and pulling down along the container. The Oxalert sachet (A) and the oxygen absorber (B) should be discarded. Place the bag on a clean, flat surface or hang on a support hook.


3.



3. Break off the tamper-evident arrow flag from the blue infusion port.

Use a compounding set with a diameter of 5.6 +/- 0.1 mm. Follow the instructions for use for the compounding set.

4.




4. Hold the base of the infusion port firmly and insert the spike straight through the center of the septum by rotating the wrist slightly if needed.

NOTE: Assure that the spike is inserted straight into the port and not at an angle.

Inspect the bag and contents for particulate matter in a well-lit environment prior to use. Discard the bag if there are any signs of discoloration or particulates.

5.



5. Hang the bag in the hanger cut and start transfer to the compounding bag